Changes in Hong Kong stocks | Hansite-B (03378) fell by more than 45% on the first day of listing, and the total market value was less than HK$2.4 billion, and the total market value was less than HK$2.4 billion

The Zhitong Finance App learned that Hansi Aite-B (03378) opened low on the first day of listing. The intraday low was HK$17.2, which is close to the lower than the offering price of HK$32. As of press release, it decreased by 45.5% to HK$17.44, with a turnover of HK$212 million and a total market value of less than HK$2.4 billion.

According to the prospectus, Hansai is a biotechnology company with independent expertise and experience in structural biology, translational medicine, and clinical development. Since 2016, Hansi Aitai has developed a product pipeline, including one core product and nine candidate products for other pipelines, namely three clinical-stage drug candidates for oncology, including core products HX009 and main products HX301 and HX044; and seven pre-clinical drug candidates, including antibody-conjugated drugs, bispecific antibodies, and monoclonal antibodies for the autoimmune and oncology markets.

On the financial side, during the track record period, Hansatec did not make a profit and recorded operating losses. In the eight months ended August 31 in 2023, 2024, and 2025, the company recorded year/period losses of 85.16 million yuan (RMB, same below), 117 million yuan, and 87.438 million yuan. The company's total overall loss mainly comes from R&D costs and administrative expenses.